Lacosamide Oral Solution
Product Images NDC 67877-732

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide Oral Solution (NDC 67877-732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Laco-cont-200ml (Laco Cont 200ml)

Lacosamide Oral Solution, USP 10 mg/mL oral solution label showing a 200 mL bottle size. The label includes instructions for pharmacists, manufacturer Alkem Laboratories Ltd. (India), and distributor Ascend Laboratories, LLC (Parsippany, NJ). It states the product is prescription-only (Rx Only) and includes temperature storage guidance and phenylketonurics warning. The NDC code 67877-732-95 is displayed along with a barcode.*

FDA Label Image

Laco-cont-465ml (Laco Cont 465ml)

Label for Lacosamide Oral Solution USP 10 mg/mL, an oral prescription solution. The bottle contains 465 mL and is manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. The label includes dosage strength, pharmacist attention notice, storage instructions, and a barcode.*

FDA Label Image

Laco-fig-1 (Laco Fig 1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing placebo and different doses of Lacosamide (200, 400, 600 mg/day) across three studies. The chart shows median percentage reduction in seizures with Lacosamide consistently higher than placebo in all studies, with exact percentages labeled on each bar.*

FDA Label Image

Laco-fig-2 (Laco Fig 2)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4,' illustrating responder rates (equal to or greater improvement) on the vertical axis and percent of patients on the horizontal axis. The graph compares placebo and Lacosamide doses of 200 mg/day, 400 mg/day, and 600 mg/day, showing trends of patient response rates across these groups.*

FDA Label Image

Laco-structure (Laco Structur)

Chemical structure diagram of the active ingredient in Lacosamide Oral Solution, showing its molecular configuration with acetamide, amide, ether, and phenyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.